MedTrace Logo

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

NCT00382668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-04-14

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.

Conditions

Interventions

DRUG

Dasatinib

Tablets, Oral, 50 mg, once daily, for one day

DRUG

Dasatinib

Tablets, Oral, 20 mg, once daily for one day

DRUG

Dasatinib

Tablets, Oral, 70 mg, once daily for one day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382668 on ClinicalTrials.gov